Dermira to Present at 15th Annual Needham Healthcare Conference

MENLO PARK, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced participation in the 15th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 12:50 p.m. ET (9:50 a.m. PT) on Tuesday, April 12, 2016, in New York City. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.

About Dermira

Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.

In addition to SEC filings, press releases, public conference calls and webcasts, we use our website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about our company, our product candidates, our planned financial and other announcements, our attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our LinkedIn page in addition to following our press releases, SEC filings, public conference calls and webcasts.

Dermira Contact
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer
650.421.7200
[email protected]

Investor Contact
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]

You May Also Be Interested In

• SEC proposes new rules for crypto asset investment contracts
• Amylyx Pharmaceuticals launches $350M common stock offering
• Wrap Technologies closes $12M stock offering at $1.40 per share